BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35257446)

  • 1. Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry.
    D'Amario D; Rodolico D; Rosano GMC; Dahlström U; Crea F; Lund LH; Savarese G
    Eur J Heart Fail; 2022 May; 24(5):871-884. PubMed ID: 35257446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex differences in the prognostic role of achieving target doses of heart failure medications: Data from the Swedish Heart Failure Registry.
    Ferrari A; Stolfo D; Uijl A; Orsini N; Benson L; Sinagra G; Mol P; de Vries ST; Dahlström U; Rosano G; Lund LH; Savarese G
    Eur J Heart Fail; 2024 May; 26(5):1101-1110. PubMed ID: 38695292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction.
    Fu M; Pivodic A; Käck O; Costa-Scharplatz M; Dahlström U; Lund LH
    Clin Res Cardiol; 2023 Jan; 112(1):167-174. PubMed ID: 36443599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry.
    Tomasoni D; Pagnesi M; Colombo G; Chiarito M; Stolfo D; Baldetti L; Lombardi CM; Adamo M; Maggi G; Inciardi RM; Loiacono F; Maccallini M; Villaschi A; Gasparini G; Montella M; Contessi S; Cocianni D; Perotto M; Barone G; Merlo M; Cappelletti AM; Rosano G; Sinagra G; Pini D; Savarese G; Metra M
    Eur J Heart Fail; 2024 Feb; 26(2):327-337. PubMed ID: 37933210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of and association between heart failure pharmacological treatments and outcomes in obese versus non-obese patients with heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry.
    Cappelletto C; Stolfo D; Orsini N; Benson L; Rodolico D; Rosano GMC; Dahlström U; Sinagra G; Lund LH; Savarese G
    Eur J Heart Fail; 2023 May; 25(5):698-710. PubMed ID: 36781199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries.
    Ouwerkerk W; Teng TK; Tromp J; Tay WT; Cleland JG; van Veldhuisen DJ; Dickstein K; Ng LL; Lang CC; Anker SD; Zannad F; Hung CL; Sawhney JPS; Naik A; Shimizu W; Hagiwara N; Wander GS; Anand I; Richards AM; Voors AA; Lam CSP
    Eur J Heart Fail; 2020 Aug; 22(8):1472-1482. PubMed ID: 32583922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden).
    Savarese G; Bodegard J; Norhammar A; Sartipy P; Thuresson M; Cowie MR; Fonarow GC; Vaduganathan M; Coats AJS
    Eur J Heart Fail; 2021 Sep; 23(9):1499-1511. PubMed ID: 34132001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
    Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
    Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
    Greene SJ; Butler J; Albert NM; DeVore AD; Sharma PP; Duffy CI; Hill CL; McCague K; Mi X; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Fonarow GC
    J Am Coll Cardiol; 2018 Jul; 72(4):351-366. PubMed ID: 30025570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry.
    Greene SJ; Butler J; Hellkamp AS; Spertus JA; Vaduganathan M; Devore AD; Albert NM; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC
    J Card Fail; 2022 Mar; 28(3):370-384. PubMed ID: 34793971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: Findings from the HF-ACTION trial.
    Pierce JB; Mentz RJ; Sun JL; Alhanti B; Whellan DJ; Kraus WE; Piña IL; Fiuzat M; O'Connor CM; Greene SJ
    Am Heart J; 2022 Sep; 251():115-126. PubMed ID: 35640729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry.
    Peri-Okonny PA; Mi X; Khariton Y; Patel KK; Thomas L; Fonarow GC; Sharma PP; Duffy CI; Albert NM; Butler J; Hernandez AF; McCague K; Williams FB; DeVore AD; Patterson JH; Spertus JA
    JACC Heart Fail; 2019 Apr; 7(4):350-358. PubMed ID: 30738978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Fonarow GC; DeVore AD; Sharma PP; Vaduganathan M; Albert NM; Duffy CI; Hill CL; McCague K; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Butler J
    J Am Coll Cardiol; 2019 May; 73(19):2365-2383. PubMed ID: 30844480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.
    Xie W; Zheng F; Song X; Zhong B; Yan L
    Int J Cardiol; 2016 Feb; 205():65-71. PubMed ID: 26720043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure.
    Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH
    Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis.
    Leite M; Sampaio F; Saraiva FA; Diaz SO; Barros AS; Fontes-Carvalho R
    ESC Heart Fail; 2023 Jun; 10(3):1822-1834. PubMed ID: 36896801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.